Autoimmunity in Retinitis Pigmentosa

This study is ongoing, but not recruiting participants.

Sponsored by:	Semmelweis University
Information provided by:	Semmelweis University
ClinicalTrials.gov Identifier:	NCT00433277

Purpose

Using local immune suppression, the trial seeks evidence for the hypothesis that autoimmunity plays a role in the pathomechanism of retinitis pigmentosa.

Condition	Intervention
Retinitis Pigmentosa	Drug: twice-daily dosage with 0.5% cyclosporine-A eyedrops

Genetics Home Reference related topics: Lenz microphthalmia syndrome oculofaciocardiodental syndrome Peters plus syndrome X-linked juvenile retinoschisis

Drug Information available for: Cyclosporin Cyclosporine Tetrahydrozoline Tetrahydrozoline hydrochloride

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Non-Randomized, Open Label, Historical Control, Single Group Assignment

Eligibility

Genders Eligible for Study:

Both

Criteria

Inclusion Criteria:

Clinical diagnosis of retinitis pigmentosa

Exclusion Criteria:

Cataract
Extremely low ERG wave amplitude (less than 8% of normal)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00433277

Locations

Hungary
Semmelweis University, Dept. of Ophthalmology
Budapest, Hungary, H-1085

Sponsors and Collaborators

Semmelweis University

Investigators

Study Director:

Zoltán Z. Nagy, M.D.

Semmelweis University, Dept. of Ophthalmology

More Information

Study ID Numbers:	KMolnar
Study First Received:	February 6, 2007
Last Updated:	February 8, 2007
ClinicalTrials.gov Identifier:	NCT00433277
Health Authority:	Hungary: National Institute of Pharmacy

Study placed in the following topic categories:

Cyclosporine
Clotrimazole
Miconazole
Eye Diseases
Tioconazole
Retinitis
Retinal Degeneration
Tetrahydrozoline

Cyclosporins
Pigmentary retinopathy
Genetic Diseases, Inborn
Retinitis Pigmentosa
Cone rod dystrophy
Eye Diseases, Hereditary
Retinal Diseases
Retinal degeneration

Additional relevant MeSH terms:

Anti-Infective Agents
Immunologic Factors
Molecular Mechanisms of Pharmacological Action
Therapeutic Uses
Antifungal Agents
Physiological Effects of Drugs

Enzyme Inhibitors
Antirheumatic Agents
Immunosuppressive Agents
Dermatologic Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009